⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iii small lymphocytic lymphoma

Every month we try and update this database with for stage iii small lymphocytic lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)NCT00947388
Recurrent Small...
Refractory Chro...
Stage III Chron...
Stage III Small...
Stage IV Chroni...
Stage IV Small ...
Bendamustine Hy...
Alemtuzumab
18 Years - Case Comprehensive Cancer Center
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaNCT00003639
Lymphoma
recombinant int...
chlorambucil
dexamethasone
idarubicin
15 Years - 70 YearsNational Cancer Institute (NCI)
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Beta Alethine in Treating Patients With Low-Grade LymphomaNCT00007839
Lymphoma
beta alethine
18 Years - National Cancer Institute (NCI)
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's LymphomaNCT00006039
Lymphoma
Small Intestine...
pegylated inter...
18 Years - Memorial Sloan Kettering Cancer Center
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantNCT00833534
Leukemia
Lymphoma
rituximab
lenalidomide
18 Years - Fred Hutchinson Cancer Center
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaNCT00278161
Leukemia
Lymphoma
Pegfilgrastim
Rituximab
Cyclophosphamid...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaNCT00110149
Lymphoma
rituximab
yttrium Y 90 ib...
18 Years - 120 YearsBeth Israel Deaconess Medical Center
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaNCT00784927
Lymphoma
rituximab
cyclophosphamid...
dexamethasone
lenalidomide
18 Years - 120 YearsMayo Clinic
Rituximab Plus Interleukin-2 in Treating Patients With LymphomaNCT00003356
Lymphoma
aldesleukin
rituximab
18 Years - 75 YearsUniversity of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)NCT00005626
Leukemia
Lymphoma
Irinotecan
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaNCT00017472
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Stage III Margi...
Stage III Small...
Stage IV Margin...
Stage IV Small ...
apolizumab
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersNCT00003572
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
peripheral bloo...
mycophenolate m...
tacrolimus
allogeneic bone...
radiation thera...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantNCT00833534
Leukemia
Lymphoma
rituximab
lenalidomide
18 Years - Fred Hutchinson Cancer Center
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerNCT00248430
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
aldesleukin
therapeutic all...
melphalan
bone marrow abl...
peripheral bloo...
18 Years - 69 YearsFred Hutchinson Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00918723
Chronic Lymphoc...
Stage I Chronic...
Stage I Small L...
Stage II Chroni...
Stage II Small ...
Stage III Chron...
Stage III Small...
Stage IV Chroni...
Stage IV Small ...
Fludarabine Pho...
Cyclophosphamid...
Rituximab
Vorinostat
18 Years - Fred Hutchinson Cancer Center
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaNCT01045928
Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerNCT00010192
B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaNCT00003204
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Small...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Small ...
cyclophosphamid...
fludarabine pho...
vincristine sul...
prednisone
rituximab
laboratory biom...
18 Years - National Cancer Institute (NCI)
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or LymphomaNCT00006252
Leukemia
Lymphoma
fludarabine pho...
Cyclophosphamid...
PBSC
G-CSF
Donor lymphocyt...
- 69 YearsAlliance for Clinical Trials in Oncology
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaNCT00551239
Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 YearsCTI BioPharma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaNCT00003639
Lymphoma
recombinant int...
chlorambucil
dexamethasone
idarubicin
15 Years - 70 YearsNational Cancer Institute (NCI)
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological CancersNCT01240525
Graft Versus Ho...
Leukemia
Lymphoma
Myeloma
Myelodysplastic...
CD4 DLI
No DLI
18 Years - 69 YearsUniversity College, London
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaNCT00275080
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic CancerNCT00005967
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
tipifarnib
18 Years - National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00918723
Chronic Lymphoc...
Stage I Chronic...
Stage I Small L...
Stage II Chroni...
Stage II Small ...
Stage III Chron...
Stage III Small...
Stage IV Chroni...
Stage IV Small ...
Fludarabine Pho...
Cyclophosphamid...
Rituximab
Vorinostat
18 Years - Fred Hutchinson Cancer Center
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaNCT00541034
Leukemia
Lymphoma
rituximab
cyclophosphamid...
pentostatin
18 Years - 120 YearsMemorial Sloan Kettering Cancer Center
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's LymphomaNCT00003605
Lymphoma
rituximab
cyclophosphamid...
- Hoag Memorial Hospital Presbyterian
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01024010
Chronic Lymphoc...
Stage 0 Chronic...
Stage I Chronic...
Stage I Small L...
Stage II Chroni...
Stage II Small ...
Stage III Chron...
Stage III Small...
Stage IV Chroni...
Stage IV Small ...
Cyclophosphamid...
Laboratory Biom...
Ofatumumab
Pentostatin
18 Years - Mayo Clinic
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or LeukemiaNCT00004084
Leukemia
Lymphoma
indium In 111 L...
yttrium Y 90 ep...
18 Years - Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's LymphomaNCT00018954
Leukemia
Lymphoma
asparaginase
cyclophosphamid...
cytarabine
daunorubicin hy...
doxorubicin hyd...
etoposide
ifosfamide
mercaptopurine
methotrexate
prednisone
vincristine sul...
conventional su...
radiation thera...
- National Institutes of Health Clinical Center (CC)
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerNCT00004061
Leukemia
Lymphoma
Oral Complicati...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
peripheral bloo...
quality-of-life...
radiation thera...
18 Years - 65 YearsNational Cancer Institute (NCI)
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerNCT00004061
Leukemia
Lymphoma
Oral Complicati...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
peripheral bloo...
quality-of-life...
radiation thera...
18 Years - 65 YearsNational Cancer Institute (NCI)
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00026351
Leukemia
Lymphoma
rituximab
pentostatin
18 Years - National Cancer Institute (NCI)
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaNCT00110149
Lymphoma
rituximab
yttrium Y 90 ib...
18 Years - 120 YearsBeth Israel Deaconess Medical Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT00725062
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
CD4+CD25+ regul...
allogeneic hema...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaNCT00003338
Lymphoma
immunoscintigra...
technetium Tc 9...
16 Years - 120 YearsGilead Sciences
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's LymphomaNCT00006039
Lymphoma
Small Intestine...
pegylated inter...
18 Years - Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01027000
Leukemia
Lymphoma
rituximab
busulfan
cyclophosphamid...
fludarabine pho...
methotrexate
sirolimus
tacrolimus
allogeneic stem...
18 Years - 69 YearsAlliance for Clinical Trials in Oncology
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01076556
Chronic Lymphoc...
Prolymphocytic ...
Recurrent Small...
Refractory Chro...
Stage I Chronic...
Stage I Small L...
Stage II Chroni...
Stage II Small ...
Stage III Chron...
Stage III Small...
Stage IV Chroni...
Stage IV Small ...
Alvocidib Hydro...
Cyclophosphamid...
Diagnostic Labo...
Pharmacological...
Rituximab
18 Years - National Cancer Institute (NCI)
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT00725062
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
CD4+CD25+ regul...
allogeneic hema...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaNCT00551239
Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 YearsCTI BioPharma
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's LymphomaNCT00443976
Non-Hodgkins Ly...
Unspecified Adu...
Aurora kinase i...
18 Years - Canadian Cancer Trials Group
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic LymphomaNCT00049413
Leukemia
Lymphoma
rituximab
cyclophosphamid...
pentostatin
18 Years - Hoag Memorial Hospital Presbyterian
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanNCT00577278
Graft Versus Ho...
Leukemia
Lymphoma
rituximab
fludarabine pho...
melphalan
sirolimus
tacrolimus
allogeneic hema...
indium In 111 i...
yttrium Y 90 ib...
laboratory biom...
18 Years - 69 YearsCity of Hope Medical Center
Beta Alethine in Treating Patients With Low-Grade LymphomaNCT00007839
Lymphoma
beta alethine
18 Years - National Cancer Institute (NCI)
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaNCT01682044
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Margina...
Stage I Small L...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Margi...
Stage III Small...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Margin...
Stage IV Small ...
pegfilgrastim
rituximab
flow cytometry
biopsy
immunohistochem...
western blottin...
19 Years - Roswell Park Cancer Institute
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaNCT00003204
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Small...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Small ...
cyclophosphamid...
fludarabine pho...
vincristine sul...
prednisone
rituximab
laboratory biom...
18 Years - National Cancer Institute (NCI)
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasNCT02213913
Adult Grade III...
B-cell Chronic ...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Progressive Hai...
Small Intestine...
Splenic Margina...
Stage 0 Chronic...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult H...
Stage I Adult I...
Stage I Chronic...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage II Adult ...
Stage II Chroni...
Stage II Small ...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Chron...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Chroni...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Testicular Lymp...
Untreated Hairy...
Waldenström Mac...
lenalidomide
etoposide
prednisone
vincristine sul...
doxorubicin hyd...
cyclophosphamid...
rituximab
quality-of-life...
laboratory biom...
18 Years - University of Chicago
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaNCT00004112
Lymphoma
rituximab
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
19 Years - 120 YearsUniversity of Nebraska
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00602836
Leukemia
Lymphoma
Rituximab
Cyclophosphamid...
Lenalidomide
Pentostatin
18 Years - 120 YearsMayo Clinic
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaNCT02037256
Adult Grade III...
B-cell Chronic ...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Progressive Hai...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Hair...
Refractory Mult...
Small Intestine...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Multipl...
Stage I Small L...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Untreated Hairy...
Waldenström Mac...
bortezomib
filgrastim
autologous hema...
18 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic CancerNCT00004132
Drug/Agent Toxi...
Leukemia
Lymphoma
Multiple Myelom...
Oral Complicati...
Radiation Toxic...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
quality-of-life...
radiation thera...
12 Years - 65 YearsNational Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological CancersNCT01240525
Graft Versus Ho...
Leukemia
Lymphoma
Myeloma
Myelodysplastic...
CD4 DLI
No DLI
18 Years - 69 YearsUniversity College, London
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHLNCT00274794
Lymphoma
filgrastim
rituximab
18 Years - The Cleveland Clinic
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaNCT00551239
Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 YearsCTI BioPharma
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaNCT00003337
Lymphoma
immunoscintigra...
technetium Tc 9...
16 Years - 120 YearsGilead Sciences
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00602836
Leukemia
Lymphoma
Rituximab
Cyclophosphamid...
Lenalidomide
Pentostatin
18 Years - 120 YearsMayo Clinic
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's LymphomaNCT00004260
Lymphoma
recombinant int...
rituximab
18 Years - Mayo Clinic
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00425802
Leukemia
Lymphoma
anti-thymocyte ...
filgrastim
graft-versus-tu...
rituximab
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
nonmyeloablativ...
total-body irra...
18 Years - 70 YearsMemorial Sloan Kettering Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: